- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07948044
Prospective Validation of the MASA Score for Detection of Previously Unknown Atrial Fibrillation (MASA-AF)
MASA (Metabolic-Atrial-Septal-Assessment) Score for Selecting Patients for Extended ECG Monitoring: A Prospective, Blinded, Single-Center Diagnostic Accuracy Cohort Study
The MASA (Metabolic-Atrial-Septal-Assessment) score is a simple 0-8 point score built from five routinely available variables: estimated glomerular filtration rate, serum triglycerides, absence of atrial septal aneurysm, left atrial diameter, and TAPSE. In a retrospective development cohort (n=246), a score of 5 or more identified patients with atrial fibrillation (AF). This prospective study will test, in consecutive patients with cardiovascular disease or stroke without known AF admitted to the Intensive Care Unit, whether a MASA score of 5 or more identifies those in whom AF is detected by continuous ECG monitoring. The score, its threshold, and the primary outcome are fixed before enrollment and will not be changed.
연구 개요
상세 설명
Background: Undetected paroxysmal atrial fibrillation (AF) is a major preventable cause of stroke. Extended ECG monitoring is effective but resource-intensive; a simple score could help select patients who need it most.
Study phases: The study was approved by the Ethics Committee of the Special Hospital for Cerebrovascular Diseases "Sveti Sava" (No. 03/4310, 30 October 2026) under the title "Development of the MASA score for assessing the probability of atrial fibrillation in a retrospective cohort of cardiology patients and its prospective validation in the intensive care unit: a single-center study." Phase 1 (retrospective score development, n=246) is completed. This registration covers Phase 2, the prospective validation in consecutive patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke, or transient ischemic attack) admitted to the Intensive Care Unit.
Pre-specified score (locked before enrollment): eGFR <60 mL/min/1.73 m² (CKD-EPI 2021) = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm ABSENT on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. Score range 0-8. Positive screen = score >=5.
Procedures: Consecutive eligible patients undergo blood sampling (serum creatinine, triglycerides) and transthoracic echocardiography (left atrial diameter, TAPSE, interatrial septum assessment) shortly after ICU admission, with heart rhythm recorded at the time of echocardiography. The MASA score is calculated by an investigator not involved in rhythm assessment. All patients, regardless of score, undergo continuous ECG monitoring during the ICU stay. ECG recordings are assessed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. AF is defined as an episode of at least 30 seconds.
Sample size: At least 61 patients with confirmed AF are required for a precise estimate of sensitivity (target 100). Enrollment continues until at least 61 (target 100) patients with confirmed AF have been enrolled; the anticipated total enrollment is approximately 700 patients, assuming a 10% AF detection rate.
Analysis: Primary-sensitivity and specificity of MASA >=5 with 95% confidence intervals. Secondary-positive and negative predictive values, area under the ROC curve, comparison with age and CHA2DS2-VASc (DeLong test), decision curve analysis, and number of patients monitored per detected AF. Pre-specified sensitivity analysis: serum creatinine >=90 umol/L instead of eGFR. Reporting will follow STARD 2015 and TRIPOD+AI 2024.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Dejan Munjiza, MD, MSc
- 전화번호: +381608018437
- 이메일: munjizad@gmail.com
연구 장소
-
-
-
Belgrade, 세르비아, 11000
- Special Hospital for Cerebrovascular Diseases "Sveti Sava"
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Consecutive adult patients with cardiovascular disease or stroke, without previously documented atrial fibrillation, admitted to the Intensive Care Unit of the Special Hospital for Cerebrovascular Diseases "Sveti Sava", Belgrade, Serbia.
설명
Inclusion Criteria:
- Age 18 years or older
- Consecutive admission to the Intensive Care Unit with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack)
- Sinus rhythm on the admission 12-lead ECG
- Transthoracic echocardiography and blood tests (serum creatinine, triglycerides) feasible shortly after admission
Exclusion Criteria:
- Any previously documented atrial fibrillation or atrial flutter
- Atrial fibrillation or atrial flutter on the admission ECG
- Permanent pacemaker or implantable cardioverter-defibrillator
- Mechanical mitral valve prosthesis or moderate-to-severe mitral stenosis
- Inadequate echocardiographic window for measurement of left atrial diameter, TAPSE or assessment of the interatrial septum
- Expected duration of continuous ECG monitoring shorter than 24 hours
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
ICU patients with cardiovascular disease or stroke without known AF
Consecutive adult patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack), without previously documented atrial fibrillation, admitted to the Intensive Care Unit. All participants have the MASA score calculated and undergo continuous ECG monitoring during the ICU stay. |
Calculation of the MASA score (range 0-8) from routinely collected data: eGFR <60 mL/min/1.73 m2 = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm absent on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. A score >=5 is considered a positive screen. The score does not influence patient management; all patients undergo continuous ECG monitoring regardless of score. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Sensitivity and Specificity of MASA Score >=5 for Detection of Atrial Fibrillation
기간: From ICU admission to ICU discharge (up to 30 days)
|
Sensitivity and specificity (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring. Atrial fibrillation is defined as an episode lasting at least 30 seconds, confirmed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. |
From ICU admission to ICU discharge (up to 30 days)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Positive and Negative Predictive Values of MASA Score >=5
기간: From ICU admission to ICU discharge (up to 30 days)
|
Positive and negative predictive values (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring. |
From ICU admission to ICU discharge (up to 30 days)
|
|
Discriminative Performance of the MASA Score
기간: From ICU admission to ICU discharge (up to 30 days)
|
Area under the ROC curve (with 95% confidence interval) of the MASA score for atrial fibrillation, compared with age and CHA2DS2-VASc score using the DeLong test. |
From ICU admission to ICU discharge (up to 30 days)
|
|
Clinical Net Benefit of MASA-Guided Monitoring
기간: From ICU admission to ICU discharge (up to 30 days)
|
Net benefit of selecting patients for extended ECG monitoring by MASA score >=5, assessed by decision curve analysis. |
From ICU admission to ICU discharge (up to 30 days)
|
|
Number of Patients Monitored per Detected Atrial Fibrillation
기간: From ICU admission to ICU discharge (up to 30 days)
|
Number of patients who would need extended ECG monitoring to detect one case of atrial fibrillation when monitoring is restricted to patients with MASA score >=5. |
From ICU admission to ICU discharge (up to 30 days)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Dejan Munjiza, MD, MSc, Special Hospital for Cerebrovascular Diseases "Sveti Sava"
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- MASA-AF-2026
- 03/4310 (기타 식별자: Ethics Committee, SB Sveti Sava, Belgrade)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
De-identified individual participant data underlying the published results, together with the analysis code, will be made available.
IPD 공유 기간
After publication of the primary results, for at least 5 years.
IPD 공유 액세스 기준
Available to qualified researchers on reasonable request to the principal investigator, for non-commercial research purposes.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ANALYTIC_CODE
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .